European Project Using Artificial Intelligence to Improve ALS Care
A new project run by a consortium of European institutions aims to improve the care of people with amyotrophic…
Articles by Forest Ray PhD
ALS Augmentative Communication Program Renamed for Advocate
Boston Children’s Hospital (BCH) is renaming its amyotrophic lateral sclerosis (ALS) Augmentative Communication Program…
COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
Radicava Out-of-pocket Assistance Program Made Easier
Mitsubishi Tanabe Pharma America announced changes to enhance its out-of-pocket assistance program for people with amyotrophic lateral sclerosis…
PrimeC Earns Orphan Drug Designation in Europe
The European Medicines Agency has granted orphan drug designation to PrimeC, an investigational combination therapy for amyotrophic lateral…
First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial
A pivotal clinical trial evaluating pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) has enrolled its first participant,…
Cytokinetics Presents COURAGE-ALS Phase 3 Trial Plan for Testing Reldesemtiv
Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic…
FDA Grants Orphan Drug Designation to SLS-005 for Slowing ALS Progression
The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to Seelos Therapeutics‘…
Radicava’s Effectiveness for ALS Not Established, Real-life Use Suggests
A review of Radicava (edaravone), an approved amyotrophic lateral sclerosis (ALS) treatment, found the medication generally well tolerated in…
Global Phase 3 Study of Oral Edaravone to Treat ALS Fully Enrolled
The Phase 3 clinical trial investigating an oral suspension formulation of edaravone (MT-1186) in treating…